No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Dalrada Financial Announces Acquisitions In Healthcare And Engineering

Editor: What To Know

  • Bonar concludes, “As Dalrada addresses market needs for bespoke parts and green energy solutions, the acquisition of CHP International Solutions further expands the Company’s capability of providing our clients cost-effective Engineering and custom precision parts solutions from a strategic geographic location.
  • By adding a product line in stem cell treatment that is led by an experienced professional team, Dalrada Health will provide alternative therapies to surgery with a drug-free option.
  • 0 billion in 2019 and is estimated to expand at a CAGR of around 5% over the forecast period.

December 28, 2020

Dalrada Financial Corp. announced the Company’s latest acquisition and letters of intent to acquire existing businesses that accelerate its 2021 global market expansion efforts in healthcare and engineering sectors.

Dalrada’s subsidiary, Dalrada Health Products, has executed Letters of Intent to acquire 100% of U.S.-based Pacific Stem Cells, LLC and International Health Group, Inc. through an all stock and cash exchange agreement. Dalrada’s subsidiary, Dalrada Precision, has also acquired a percentage of shares and ownership of CHP Industrial Solutions located in Malaysia.

Dalrada Financial notes the acquisition of Pacific Stem Cells, LLC would further expand Dalrada Health’s product and services offerings in the healthcare industry. By adding a product line in stem cell treatment that is led by an experienced professional team, Dalrada Health will provide alternative therapies to surgery with a drug-free option. Located in Newport Beach, California, Pacific Stem Cells, LLC holds a solid reputation with a loyal customer base. This new product line allows Dalrada Health to offer state-of-the-art alternative therapies while sustaining profit margins.

The global stem cells market size is expected to reach USD 17.9 billion by 2027, expanding at a CAGR of 8.2%.

Dalrada Health’s addition of International Health Group, Inc. (“IHG”) would add a healthcare training, certification, and staffing service to Dalrada’s portfolio for immediately addressing career placement needs in a burgeoning industry. Since 2006, IHG has created the next generation of nurses and medical assistants with more than 6,000 students graduating from the program. IHG is well-established and continues to certify talented individuals who provide quality compassionate care to thousands of patients.

An industry report highlights The American Nurses Association declares nursing careers are, “…in high demand, with more jobs available through 2022 than any other profession in the U.S.” The report continues to explain, “…nursing is one of the fastest-growing occupations in the U.S.”, according to BLS Employment Projections for 2018-2028. The U.S. healthcare staffing market size for the period of 2020 – 2027 was valued at USD 17.0 billion in 2019 and is estimated to expand at a CAGR of around 5% over the forecast period.

Brian Bonar, Dalrada Financial Chief Executive Officer states, “The acquisitions of Pacific Stem Cells, LLC and International Health Group, Inc. would speed Dalrada’s expansion efforts in the healthcare market while solidifying a channel for existing product and service adoption.”

In addition, Dalrada Financial also acquired a percentage of shares and ownership of Malaysian ISO 9001:2015 & AS9100:2016 certified company CHP Industrial Solutions. This acquisition bolsters Dalrada Precision’s computer numerical control (CNC) and custom part manufacturing capabilities with added machinery, quality assurance processes and teams, and additional factory locations in Malaysia. CHP Industrial Solutions’ customer base includes Fortune 100 clients in semiconductor and data storage, automotive, and aviation. The acquisition of CHP Industrial Solutions allows Dalrada Precision to continue its expansion efforts into vertical markets including major airlines, biotechnology, pharmaceutical, and technology sectors.

The global precision parts market size is projected to reach USD 300 billion by 2025, anticipating a growth rate of 10% during 2020-2025.

Bonar concludes, “As Dalrada addresses market needs for bespoke parts and green energy solutions, the acquisition of CHP International Solutions further expands the Company’s capability of providing our clients cost-effective Engineering and custom precision parts solutions from a strategic geographic location.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy